Premium
THREE PHASE 1/2, OPEN‐LABEL STUDIES OF CEREBLON E3 LIGASE MODULATOR (CELMOD)‐BASED REGIMENS IN NEWLY DIAGNOSED (ND) OR RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL)
Author(s) -
Morschhauser F.,
Nowakowski G. S.,
Cartron G.,
Kesanakurthy V.,
Gkasiamis A.,
Patah P.,
Delarue R.,
Wang T.,
Li J.,
Xian D.,
Fox C. P.,
Martin P.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.173_2880
Subject(s) - obinutuzumab , medicine , lenalidomide , rituximab , lymphoma , cereblon , diffuse large b cell lymphoma , oncology , follicular lymphoma , cancer research , chemistry , multiple myeloma , ubiquitin ligase , biochemistry , ubiquitin , gene
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom